A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

NCT ID: NCT02498288

Last Updated: 2017-06-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2013-07-15

Brief Summary

This is an open-label, crossover, randomized, single dose, three treatments, three periods and six sequences, single dosage, balanced study to determine Bioequivalence of Isotretinoin. Bioequivalence will be compared between the reference medication one (T1) vs the test medication (T3): (T1 vs T3); and the reference medication two (T2), vs test medication (T3): (T2 vs T3). Finally, treatments T1 vs T2 will be compared statistically to determine if they are bioequivalent.

Conditions

Acne Vulgaris

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Isotretinoin Arm

All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.

Group Type: EXPERIMENTAL

Isotretinoin: Reference Medication 1

Intervention Type: DRUG

Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Isotretinoin: Reference Medication 2

Intervention Type: DRUG

Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Isotretinoin: Test Medication

Intervention Type: DRUG

Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.

Interventions

Isotretinoin: Reference Medication 1

Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Intervention Type: DRUG

Isotretinoin: Reference Medication 2

Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Intervention Type: DRUG

Isotretinoin: Test Medication

Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Included in study will be male volunteers.
• Ages between 18 and 45 years old.
• BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2).
• Anti-doping tests negative results.
• Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B surface antigen), and rapid plasma regain (RPR; syphilis test).
• Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values.
• Normal Electrocardiogram (ECG) and Chest X-rays.
• Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and after each dosification period.
• Obtain a grade of zero in the C-SSRS.
• Signed the Informed Consent corresponding to the bioequivalence study.
• In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant".

Exclusion Criteria

• Electrocardiographic Anomalies; radiological
• Anti-doping tests positive results,
• Positive results regarding RPR; HIV and HBsAg tests.
• Personal or family history of allergy to medication in question.
• Having any kind of allergy, since these persons are in higher risk of suffering from medication allergy.
• Tobacco use.
• Persons undergoing any medical treatment.
• Existence of concurrent or intercurrent disease.
• History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia).
• Existence of justified doubt regarding questionnaire answers truthfulness.
• Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study.
• Presence of clinically important gastrointestinal diseases or malabsorption history during the last year.
• Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption.
• Drugs or alcohol addiction history requiring treatment.
• Refuse to take the scale 'C-SSRS, before and after each dosification period.
• Obtain a grade greater than zero in the C-SSRS.
• Do not sign the Informed Consent corresponding to the bioequivalence study.
• Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Monterrey, Nuevo León, Mexico

Countries

Mexico

Other Identifiers

200115

Identifier Type: -

Identifier Source: org_study_id